LRMR – larimar therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Larimar Therapeutics (LRMR) was upgraded by Truist Financial Corporation to "strong-buy".
Larimar Therapeutics (LRMR) had its price target raised by Wedbush from $12.00 to $13.00. They now have an "outperform" rating on the stock.
Larimar Therapeutics GAAP EPS of -$0.73 misses by $0.22 [Seeking Alpha]
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
Form S-8 Larimar Therapeutics,
Form 10-K Larimar Therapeutics, For: Dec 31
Form 8-K Larimar Therapeutics, For: Mar 19
Form SCHEDULE 13D/A Larimar Therapeutics, Filed by: Flynn James E
Form 4 Larimar Therapeutics, For: Feb 27 Filed by: Deerfield Mgmt HIF, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.